search
Back to results

Establishment and Assessment of the HVPG Using Biofluid Mechanics (HVPGBFM) (HVPGBFM)

Primary Purpose

Liver Cirrhosis, Hypertension, Portal

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
HVPG measurement
Sponsored by
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Liver Cirrhosis focused on measuring Liver Cirrhosis, Hypertension, Portal, Hepatic Venous Pressure Gradient (HVPG), Biofluid Mechanics, Noninvasive

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Be at least 18 years of age.
  • Patients with cirrhosis or portal hypertension, scheduled for HVPG measurement.

Exclusion Criteria:

  • Female patients who are pregnant or nursing.
  • Patients who are medically unstable, terminally or seriously ill, or patients whose clinical course is unpredictable.
  • Patients with clinically unstable cardiac disease, for example: congenital heart defect, arrhythmia, uncontrolled heart failure (NYHA Class IV).
  • Patients with respiratory distress syndrome or clinically unstable pulmonary disease, for example: pulmonary hypertension, pulmonary emboli, pulmonary vasculitis, emphysema.
  • Patients with severe coagulation disorders.
  • Patients with unstable occlusive disease or thrombosis within the hepatic, portal, or mesenteric veins.
  • Patients who are allergic to iodinated contrast.

Sites / Locations

  • Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of MedicineRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

HVPG

Arm Description

Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.

Outcomes

Primary Outcome Measures

Correlation between HVPGBFM and HVPG by Bland-Altman plot.
The numeric correlation between HVPGBFM and HVPG will be analysed by using Bland and Altman's limits of agreement analysis.
Correlation between HVPGBFM and HVPG by linear regression analysis.
The numeric relationship between HVPGBFM and HVPG will be analysed by using linear regression analysis.

Secondary Outcome Measures

Full Information

First Posted
February 25, 2018
Last Updated
December 12, 2018
Sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Collaborators
RenJi Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT03470389
Brief Title
Establishment and Assessment of the HVPG Using Biofluid Mechanics (HVPGBFM)
Acronym
HVPGBFM
Official Title
Establishment and Assessment of the HVPG Using Biofluid Mechanics (HVPGBFM)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Unknown status
Study Start Date
March 20, 2018 (Actual)
Primary Completion Date
September 2020 (Anticipated)
Study Completion Date
September 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Collaborators
RenJi Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is a prospective, non-controlled, multicentre trial in patients with cirrhosis or portal hypertension. In this study, the investigators aim to establish the HVPG using biofluid mechanics (HVPGBFM) model using biofluid mechanics methods and validate the HVPGBFM model. A total of 200 patients will be recruited in this study and each patient will undergo computed tomography, blood tests, Doppler ultrasound and HVPG measurement. The study consists of two independent and consecutive cohorts: original cohort (100 patients) and validation cohort (100 patients). The researchers will establish and improve the HVPGBFM model in the original cohort and assess the model in the validation cohort.
Detailed Description
Consecutive patients are randomly assigned 1:1 to either the original cohort or the validation cohort. Randomization is based on the computer-generated random digits table. This study consists of two independent and consecutive stages: Establishment and improvement of the HVPGBFM model: For 100 patients in the original cohort, biofluid mechanics specialists will use each patient's computed tomography, blood tests, Doppler ultrasound and HVPG results to adjust the parameters of the HVPGBFM model in order to make each patient's HVPGBFM and HVPG values match well. Assessment of the HVPGBFM model: For 100 patients in the validation cohort, biofluid mechanics specialists will use each patient's computed tomography, blood tests and Doppler ultrasound results to calculate each patient's HVPGBFM according to the HVPGBFM model established previously. Biofluid mechanics specialists will make no changes to the HVPGBFM model and will have no access to patients' HVPG results in this cohort. Finally, the researchers will compare each patient's HVPGBFM and HVPG value and make an assessment of the HVPGBFM model. Each patient's HVPG measurement will be performed after finishing computed tomography, blood tests and Doppler ultrasound. These results and other clinical data will be inaccessible to professionals for HVPG measurements in order to prevent certain biases. Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Cirrhosis, Hypertension, Portal
Keywords
Liver Cirrhosis, Hypertension, Portal, Hepatic Venous Pressure Gradient (HVPG), Biofluid Mechanics, Noninvasive

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
HVPG
Arm Type
Experimental
Arm Description
Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
Intervention Type
Procedure
Intervention Name(s)
HVPG measurement
Other Intervention Name(s)
Blood test, Doppler ultrasound, Computed tomography
Intervention Description
Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
Primary Outcome Measure Information:
Title
Correlation between HVPGBFM and HVPG by Bland-Altman plot.
Description
The numeric correlation between HVPGBFM and HVPG will be analysed by using Bland and Altman's limits of agreement analysis.
Time Frame
7 days
Title
Correlation between HVPGBFM and HVPG by linear regression analysis.
Description
The numeric relationship between HVPGBFM and HVPG will be analysed by using linear regression analysis.
Time Frame
7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be at least 18 years of age. Patients with cirrhosis or portal hypertension, scheduled for HVPG measurement. Exclusion Criteria: Female patients who are pregnant or nursing. Patients who are medically unstable, terminally or seriously ill, or patients whose clinical course is unpredictable. Patients with clinically unstable cardiac disease, for example: congenital heart defect, arrhythmia, uncontrolled heart failure (NYHA Class IV). Patients with respiratory distress syndrome or clinically unstable pulmonary disease, for example: pulmonary hypertension, pulmonary emboli, pulmonary vasculitis, emphysema. Patients with severe coagulation disorders. Patients with unstable occlusive disease or thrombosis within the hepatic, portal, or mesenteric veins. Patients who are allergic to iodinated contrast.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jiayun Lin
Phone
+86 18017370556
Email
lin_jiayun@outlook.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Meng Luo
Organizational Affiliation
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Official's Role
Study Chair
Facility Information:
Facility Name
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
City
Shanghai
ZIP/Postal Code
200011
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jiayun Lin
Phone
18017370556
Email
lin_jiayun@outlook.com
First Name & Middle Initial & Last Name & Degree
Meng Luo
First Name & Middle Initial & Last Name & Degree
Jiayun Lin

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
31796472
Citation
Lin JY, Zhang CH, Zheng L, Li HJ, Zhu YM, Fan X, Li F, Xia Y, Huang MZ, Yang SH, Qi XL, Huo HZ, Chen HS, Lou XL, Luo M. Establishment and assessment of the hepatic venous pressure gradient using biofluid mechanics (HVPGBFM): protocol for a prospective, randomised, non-controlled, multicentre study. BMJ Open. 2019 Dec 3;9(12):e028518. doi: 10.1136/bmjopen-2018-028518.
Results Reference
derived

Learn more about this trial

Establishment and Assessment of the HVPG Using Biofluid Mechanics (HVPGBFM)

We'll reach out to this number within 24 hrs